Literature DB >> 22403241

Interaction between NFκB and NFAT coordinates cardiac hypertrophy and pathological remodeling.

Qinghang Liu1, Yi Chen, Mannix Auger-Messier, Jeffery D Molkentin.   

Abstract

RATIONALE: Both nuclear factors of activated T cells (NFAT) and nuclear factor-κB (NFκB) are Rel homology domain (RHD)-containing transcription factors whose independent activities are critically involved in regulating cardiac hypertrophy and failure.
OBJECTIVE: To determine the potential functional interaction between NFAT and NFκB signaling pathways in cardiomyocytes and its role in cardiac hypertrophy and remodeling. METHODS AND
RESULTS: We identified a novel transcriptional regulatory mechanism whereby NFκB and NFAT directly interact and synergistically promote transcriptional activation in cardiomyocytes. We show that the p65 subunit of NFκB coimmunoprecipitates with NFAT in cardiomyocytes, and this interaction maps to the RHD within p65. Overexpression of the p65-RHD disrupts the association between endogenous p65 and NFATc1, leading to reduced transcriptional activity. Overexpression of IκB kinase β (IKKβ) or p65-RHD causes nuclear translocation of NFATc1, and expression of a constitutively nuclear NFATc1-SA mutant similarly facilitated p65 nuclear translocation. Combined overexpression of p65 and NFATc1 promotes synergistic activation of NFAT transcriptional activity in cardiomyocytes, whereas inhibition of NFκB with IκBαM or dominant negative IKKβ reduces NFAT activity. Importantly, agonist-induced NFAT activation is reduced in p65 null mouse embryonic fibroblasts (MEFs) compared with wild-type MEFs. In vivo, cardiac-specific deletion of p65 using a Cre-loxP system causes a ≈50% reduction in NFAT activity in luciferase reporter mice. Moreover, ablation of p65 in the mouse heart decreases the hypertrophic response after pressure overload stimulation, reduces the degree of pathological remodeling, and preserves contractile function.
CONCLUSIONS: Our results suggest a direct interaction between NFAT and NFκB that effectively integrates 2 disparate signaling pathways in promoting cardiac hypertrophy and ventricular remodeling.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22403241      PMCID: PMC3341669          DOI: 10.1161/CIRCRESAHA.111.260729

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  51 in total

Review 1.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity.

Authors:  M Karin; Y Ben-Neriah
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

Review 2.  Cytoplasmic signaling pathways that regulate cardiac hypertrophy.

Authors:  J D Molkentin; G W Dorn
Journal:  Annu Rev Physiol       Date:  2001       Impact factor: 19.318

Review 3.  Left ventricular hypertrophy: pathogenesis, detection, and prognosis.

Authors:  B H Lorell; B A Carabello
Journal:  Circulation       Date:  2000-07-25       Impact factor: 29.690

4.  Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes.

Authors:  N H Purcell; G Tang; C Yu; F Mercurio; J A DiDonato; A Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

5.  Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy.

Authors:  T Taigen; L J De Windt; H W Lim; J D Molkentin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

6.  Cyclosporine reduces left ventricular mass with chronic aortic banding in mice, which could be due to apoptosis and fibrosis.

Authors:  G Yang; T Meguro; C Hong; K Asai; G Takagi; V L Karoor; J Sadoshima; D E Vatner; S P Bishop; S F Vatner
Journal:  J Mol Cell Cardiol       Date:  2001-08       Impact factor: 5.000

Review 7.  Multiple facets of NF-κB in the heart: to be or not to NF-κB.

Authors:  Joseph W Gordon; James A Shaw; Lorrie A Kirshenbaum
Journal:  Circ Res       Date:  2011-04-29       Impact factor: 17.367

Review 8.  Calcineurin and beyond: cardiac hypertrophic signaling.

Authors:  J D Molkentin
Journal:  Circ Res       Date:  2000-10-27       Impact factor: 17.367

9.  Calcineurin pathway is required for endothelin-1-mediated protection against oxidant stress-induced apoptosis in cardiac myocytes.

Authors:  T Kakita; K Hasegawa; E Iwai-Kanai; S Adachi; T Morimoto; H Wada; T Kawamura; T Yanazume; S Sasayama
Journal:  Circ Res       Date:  2001-06-22       Impact factor: 17.367

10.  Cyclosporin A inhibits cardiac hypertrophy and enhances cardiac dysfunction during postinfarction failure in rats.

Authors:  E Oie; R Bjørnerheim; O P Clausen; H Attramadal
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-06       Impact factor: 4.733

View more
  84 in total

Review 1.  Metabolic stress in the myocardium: adaptations of gene expression.

Authors:  Peter A Crawford; Jean E Schaffer
Journal:  J Mol Cell Cardiol       Date:  2012-06-21       Impact factor: 5.000

2.  NF-κB activation is cell type-specific in the heart.

Authors:  Efraín E Rivera-Serrano; Barbara Sherry
Journal:  Virology       Date:  2016-12-30       Impact factor: 3.616

Review 3.  Long non-coding RNA: a versatile regulator of the nuclear factor-κB signalling circuit.

Authors:  Xiaohua Mao; Zhenyi Su; Adnan K Mookhtiar
Journal:  Immunology       Date:  2017-01-19       Impact factor: 7.397

4.  MITF interacts with the SWI/SNF subunit, BRG1, to promote GATA4 expression in cardiac hypertrophy.

Authors:  Gaurav Mehta; Sivarajan Kumarasamy; Jian Wu; Aaron Walsh; Lijun Liu; Kandace Williams; Bina Joe; Ivana L de la Serna
Journal:  J Mol Cell Cardiol       Date:  2015-09-24       Impact factor: 5.000

5.  A-kinase-anchoring protein-Lbc anchors IκB kinase β to support interleukin-6-mediated cardiomyocyte hypertrophy.

Authors:  Cosmo Damiano del Vescovo; Susanna Cotecchia; Dario Diviani
Journal:  Mol Cell Biol       Date:  2012-10-22       Impact factor: 4.272

6.  Cardiomyocyte p65 nuclear factor-κB is necessary for compensatory adaptation to pressure overload.

Authors:  Hadi Javan; Amanda M Szucsik; Ling Li; Christin L Schaaf; Mohamed E Salama; Craig H Selzman
Journal:  Circ Heart Fail       Date:  2014-12-05       Impact factor: 8.790

7.  Role of interferon regulatory factor 4 in the regulation of pathological cardiac hypertrophy.

Authors:  Ding-Sheng Jiang; Zhou-Yan Bian; Yan Zhang; Shu-Min Zhang; Yi Liu; Rui Zhang; Yingjie Chen; Qinglin Yang; Xiao-Dong Zhang; Guo-Chang Fan; Hongliang Li
Journal:  Hypertension       Date:  2013-04-15       Impact factor: 10.190

8.  Ufm1-Specific Ligase Ufl1 Regulates Endoplasmic Reticulum Homeostasis and Protects Against Heart Failure.

Authors:  Jie Li; Guihua Yue; Wenxia Ma; Aizhen Zhang; Jianqiu Zou; Yafei Cai; Xiaoli Tang; Jun Wang; Jinbao Liu; Honglin Li; Huabo Su
Journal:  Circ Heart Fail       Date:  2018-10       Impact factor: 8.790

9.  Do multiple nuclear factor kappa B activation mechanisms explain its varied effects in the heart?

Authors:  Rajesh Kumar; Qian Chen Yong; Candice M Thomas
Journal:  Ochsner J       Date:  2013

10.  Cardiac-restricted Overexpression of TRAF3 Interacting Protein 2 (TRAF3IP2) Results in Spontaneous Development of Myocardial Hypertrophy, Fibrosis, and Dysfunction.

Authors:  Manjunath Yariswamy; Tadashi Yoshida; Anthony J Valente; Hemanth Kumar Kandikattu; Siva S V P Sakamuri; Jalahalli M Siddesha; Sergiy Sukhanov; Zubaida Saifudeen; Lixin Ma; Ulrich Siebenlist; Jason D Gardner; Bysani Chandrasekar
Journal:  J Biol Chem       Date:  2016-07-27       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.